Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nb120
- Development stage
- Unknown
- Lead developer
- The Second Hospital of Nanjing
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nb120 is a therapeutic nanobody (single-domain antibody) developed by The Second Hospital of Nanjing for the treatment of severe fever with thrombocytopenia syndrome (SFTS). SFTS is a high-mortality infectious disease caused by the SFTS virus (SFTSV), a tick-borne bunyavirus. Nb120 is designed to bind specifically to the SFTSV, likely targeting the viral envelope glycoproteins (Gn or Gc) to neutralize the virus and prevent host cell entry. It is currently undergoing evaluation in a Phase I/II clinical trial (ChiCTR2500113092) to determine its safety, pharmacokinetics, and clinical efficacy in patients with acute SFTS infection.
- Other names
- Nb120 antibodyNb-120 antibodyNb 120 antibodyNb120 nanobodyNb-120 nanobodyNb 120 nanobody
02
Targets
SFTSV Gn (Severe fever with thrombocytopenia syndrome virus glycoprotein Gn)Severe fever with thrombocytopenia syndrome virus glycoprotein Gc
Beyond the preview
Go deeper on Nb120.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nb120.